Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 6,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Terminated No phase listed Observational

Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury

NCT01547065
View directory record Official record
Conditions
Subjects Undergoing Cardiac or Major Surgery Where TEE is Used as a Matter of Routine
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Nov 5, 2026, 5:45 AM EST
Completed Phase 1Phase 2 Interventional

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease

NCT01001351
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Fresno, California • San Diego, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Nov 5, 2026, 5:45 AM EST
Completed Not applicable Interventional

High Powered Stone Dusting vs. Fragmentation and Basketing at Time of Ureteroscopy

NCT05006937
View directory record Official record
Conditions
Kidney Stone, Ureteral Stone
Interventions
Dusting, Basket extraction
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Completed Not applicable Interventional

Shared Decision Making and Renal Supportive Care

NCT02405312
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
advance care planning
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Nov 5, 2026, 5:45 AM EST
Recruiting Phase 1 Interventional

Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia

NCT03723564
View directory record Official record
Conditions
Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis, Lower Urinary Tract Obstructive Syndrome
Interventions
Lactated Ringers Solution for Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 5, 2026, 5:45 AM EST
Terminated Phase 4 Interventional

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

NCT00476619
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
erythropoeitin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Nov 5, 2026, 5:45 AM EST
Recruiting No phase listed Observational

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

NCT07006831
View directory record Official record
Conditions
Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function, Cell-free DNA, NGS
Interventions
Not listed
Lead sponsor
Devyser Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Active, not recruiting Phase 1 Interventional

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

NCT02320045
View directory record Official record
Conditions
Renal Insufficiency
Interventions
ITCA 650 (Exenatide in osmotic mini pump)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
25 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Nov 5, 2026, 5:45 AM EST
Active, not recruiting Not applicable Interventional Results available

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

NCT03075072
View directory record Official record
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Vancomycin Dose Optimization in Obesity

NCT06601257
View directory record Official record
Conditions
Pharmacokinetics and Pharmacodynamics
Interventions
Vancomycin (IV)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Completed No phase listed Observational

Pathways Project: Kidney Supportive Care

NCT04125537
View directory record Official record
Conditions
Kidney Diseases, Chronic Kidney Diseases, End Stage Renal Disease, End Stage Renal Disease on Dialysis, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
IHI Breakthrough Collaborative Model
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Arvada, Colorado • Thornton, Colorado • Westminster, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 5, 2026, 5:45 AM EST
Active, not recruiting No phase listed Observational

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Terminated Not applicable Interventional Results available

Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters

NCT02796300
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Bioflo Dialysis Catheter, Palindrome Dialysis Catheter
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Nov 5, 2026, 5:45 AM EST
Terminated Phase 2 Interventional Results available

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

NCT01147536
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
HSPPC-96
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Albany, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Nov 5, 2026, 5:45 AM EST
Completed No phase listed Observational

Seroprevalence of Hepatitis E in People With an Organ Transplant

NCT02190253
View directory record Official record
Conditions
Hepatitis E
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Completed Not applicable Interventional

Pre-operative Evaluation of Kidney & Pancreas Transplant Patients

NCT00580437
View directory record Official record
Conditions
Kidney Transplantation, Pancreas Transplantation
Interventions
Dobutamine Stress Echocardiogram
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Nov 5, 2026, 5:45 AM EST
Terminated Phase 3 Interventional

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

NCT01582672
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Standard Treatment, AGS-003
Drug · Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
88
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Nov 5, 2026, 5:45 AM EST
Completed No phase listed Observational

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

NCT03924219
View directory record Official record
Conditions
Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
Interventions
CMV T cell Immunity Assay
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Recruiting Not applicable Interventional

Interventions for Promoting Kidney Transplant Empowerment

NCT06655857
View directory record Official record
Conditions
Kidney Transplant Waitlisting
Interventions
Usual Care, Community Health Worker Assistance, Intervention Providers
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 5, 2026, 5:45 AM EST
Completed No phase listed Observational

Role of Nox2 in CNI-induced Renal Fibrosis

NCT01674465
View directory record Official record
Conditions
Kidney Disease
Interventions
Hypoxyprobe-1
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Nov 5, 2026, 5:45 AM EST
Active, not recruiting No phase listed Observational

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

NCT04414111
View directory record Official record
Conditions
DGF, Kidney Transplant; Complications
Interventions
Highly suppressive Treg measurement
Diagnostic Test
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Bernardino, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 5, 2026, 5:45 AM EST
Completed Phase 2 Interventional Results available

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

NCT01666951
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro tablets, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Nov 5, 2026, 5:45 AM EST
Completed Phase 2 Interventional

Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients

NCT00062712
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 5, 2026, 5:45 AM EST